How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Lanthanide-Enhancers in the Radiotherapy of Cancer

Organization name

IMG Innovations-Management GmbH (Kaiserslautern)



In Germany alone every year about 400.000 people develop cancer. The radiation therapy is widely used as a method of treatment. Cancer cells will be harmed more, because they are more sensitive than healthy cells to ionizing radiation. Nevertheless to reduce the cancer cell growth, significantly high doses of radiation have to be used. But this leads to unwanted side effects.

Locally acting enhancers can increase the radiation, so that the cumulative dose is reduced and at the same time the ionizing effect in the tumor tissue itself is increased. Furthermore the radiation enhancer should not be toxic for the healthy tissue.

The invention uses lanthanides compounds, which are coupled to biodegradable lactic acid polymers and intensify radiation. The problem of unintended polymer accumulation in the body is avoided by the nanoparticles’ biodegradability. These particles can be introduced locally in the tumor tissue. For the radiation-potentiating effect neutron radiation is not necessary. It is sufficient to use photon radiation, which is produced by X-ray machines. These machines exist usually in doctor’s surgeries, so that more widespread application of radiation enhancer is possible.


The lanthanide radiation enhancer can be disposed in all cancer treatments, which use radiation therapy. They ensure a more efficient combat against the tumor tissue by local enhancement of the radiation in the tumor and thus a lower burden for the patient through a reduced cumulative dose.


  • Increased efficiency: locally increased radiation dose, decreased cumulative dose
  • X-rays applicable
  • The lactic acid polymer PLGA is an approved adjuvant for pharmaceutical applications
  • PLGA-coupled lanthanide nanoparticles are biodegradable

Status of development

Meaningful tests based on cell cultures

Patent situation

European patent application, international patent application possible

Rights available

Exclusive or non-exclusive licenses plusoptions on licenses.

Our reference: UMZ283

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries